Dr Alessandro Russo

  • University of Messina
  • Other, Medicine And Medical Sciences
  • Italy

My co-authors include

Professor VINCENZO ADAMO
MICHELE DE TURSI
francesco pepe

Find me at

My Publications

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes ...

  • Advances in Therapy
  • January 2020

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major...

  • Cancers
  • January 2020

RET fusions in solid tumors

  • Cancer Treatment Reviews
  • December 2019

55P Incidence and clinical implications of late immune-related adverse events in long r...

  • Annals of Oncology
  • December 2019

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and op...

  • Translational Cancer Research
  • December 2019

Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biom...

  • Cancers
  • November 2019

O.01 Challenges of Interpreting NGS Liquid Biopsy (LB) Results in Advanced NSCLC: Are E...

  • Journal of Thoracic Oncology
  • November 2019

Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Ac...

  • JCO Precision Oncology
  • November 2019

Liquid biopsy tracking of lung tumor evolutions over time

  • Expert Review of Molecular Diagnostics
  • October 2019

Concomitant medications during immune checkpoint blockage in cancer patients: Novel ins...

  • Critical Reviews in Oncology/Hematology
  • October 2019

1995PApplication of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC pat...

  • Annals of Oncology
  • October 2019

P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients’ Stratific...

  • Journal of Thoracic Oncology
  • October 2019

Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A ...

  • Cancers
  • July 2019

How I treat ALK-positive non-small cell lung cancer

  • ESMO Open
  • July 2019

Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (...

  • Journal of Clinical Oncology
  • May 2019

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhi...

  • International Journal of Molecular Sciences
  • March 2019

Immunotherapy use in patients with hiv and non-small-cell lung cancer: Current data

  • Journal of Immunotherapy and Precision Oncology
  • January 2019

The changing scenario of 1 st line therapy in non-oncogene addicted NSCLCs in the era ...

  • Critical Reviews in Oncology/Hematology
  • October 2018

P1.04-28 Baseline Markers of Inflammation and Outcome with Nivolumab in Pretreated Non ...

  • Journal of Thoracic Oncology
  • October 2018

Acquired resistance in oncogene-addicted non-small-cell lung cancer

  • Future Oncology
  • June 2018

Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymph...

  • Journal of Cellular Physiology
  • April 2018

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic...

  • BMC Cancer
  • January 2018

E22Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dN...

  • Annals of Oncology
  • October 2017

N2Retrospective analysis of the therapeutic efficacy of platinum/etoposide schedules in...

  • Annals of Oncology
  • October 2017

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going

  • Critical Reviews in Oncology/Hematology
  • September 2017

Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic cast...

  • Expert Opinion on Pharmacotherapy
  • May 2017

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient H...

  • Journal of Thoracic Oncology
  • January 2017

P1.06-046 Can We Better Manage Advanced NSCLC in the Elderly with the New Therapeutic A...

  • Journal of Thoracic Oncology
  • January 2017

Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site

  • Cancer Biology & Therapy
  • August 2016

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatm...

  • OncoTargets and Therapy
  • July 2016

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or thi...

  • Oncotarget
  • June 2016

Progression patterns after EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated (EGFR...

  • Journal of Clinical Oncology
  • May 2016

Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to ove...

  • Expert Review of Anticancer Therapy
  • May 2016

H44Epidermal Growth Factor Receptor mutational status predicts patterns of metastatic s...

  • Annals of Oncology
  • October 2015

H47The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild...

  • Annals of Oncology
  • October 2015

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old suc...

  • Oncotarget
  • June 2015

147P * DIFFERENT METASTATIC PATTERN ACCORDING TO THE EGFR MUTATIONAL STATUS IN A COHORT...

  • Annals of Oncology
  • April 2015

159P * IMPACT OF MAINTENANCE PEMETREXED IN THE MANAGEMENT OF NON-PROGRESSING MALIGNANT ...

  • Annals of Oncology
  • April 2015

Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2...

  • OncoTargets and Therapy
  • February 2015

NSCLC and HER2: Between Lights and Shadows

  • Journal of Thoracic Oncology
  • December 2014

Impact of EGFR tyrosine kinase inhibitors in the management of brain metastases from EG...

  • Journal of Clinical Oncology
  • May 2014

47P TREATMENT OPTIONS FOR SMALL CELL LUNG CANCER: DOES LANREOTIDE REPRESENT A NEW CHOICE?

  • Lung Cancer
  • May 2013